{
    "clinical_study": {
        "@rank": "104223", 
        "arm_group": [
            {
                "arm_group_label": "Abraxane 150 mg/m\u00b2 Intravenous (IV)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "CC-486 orally plus Abraxane IV", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "A phase 2, open-label randomized, multicenter trial to compare CC-486 in combination with\n      Abraxane administered weekly with respect to overall survival, objective tumor response rate\n      and Progression-Free Survival (PFS) in participants diagnosed with metastatic malignant\n      melanoma."
        }, 
        "brief_title": "Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy na\u00efve Metastatic Melanoma", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Metastatic Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "The study will consist of the following phases:\n\n        -  Screening (Baseline) Assessments:  Performed within 21 days of randomization.\n\n        -  Randomization: Subjects will be randomized within 21 days of starting their Baseline\n           assessments.\n\n        -  Treatment: Therapy may continue in the absence of clinically significant disease\n           progression and unacceptable toxicity.\n\n        -  Response Assessments:  Subjects will be evaluated by investigators for CR, PR, stable\n           or progressive disease every 6 weeks from the start of treatment until progressive\n           disease is documented.\n\n      Responders and subjects with stable disease (SD) should continue on study unless they\n      develop unacceptable toxicity, they start a new anticancer therapy, withdrawal of consent,\n      physician decision or death.\n\n        -  End of Study (EOS)/Treatment Evaluation:  At the time subjects are removed from study,\n           laboratory and clinical evaluations will be performed.\n\n        -  Follow-up for Disease Progression:\n\n           - Subjects who stop treatment prior to developing disease progression should be\n           followed without further treatment until progressive disease is documented or until the\n           treating physician feels additional treatment is required.\n\n        -  Follow-up for Survival:\n\n             -  Post study, subject survival status will be monitored on a monthly basis for 6\n                months from discontinuation from the study and every 3 months thereafter, until\n                death or study termination in all subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Histologically or cytologically confirmed cutaneous BRAF wild-type malignant\n             melanoma with evidence of metastasis (Stage IV).\n\n             2. No prior cytotoxic chemotherapy for metastatic malignant melanoma is permitted.\n             No prior adjuvant cytotoxic chemotherapy is permitted.\n\n               -  Up to one prior regimen with the following classes of agents is permitted:\n\n                  o Targeted biologic agents (e.g. interleukin 2 [IL-2], granulocyte macrophage\n                  colony stimulating factor [GM-CSF], other cytokines or unarmed monoclonal\n                  antibodies)\n\n                  o Targeted small molecule inhibitors (e.g., kinase inhibitors, heat shock\n                  protein [HSP] inhibitors, etc.).\n\n                    -  Immune checkpoint inhibitors (e.g. anti-CTLA4, anti-PD1, anti-PD-L1).\n\n                    -  Prior adjuvant therapy with interferon  and/or vaccines is permitted.\n\n               -  Prior treatments should be completed 4 weeks prior to enrollment in the study\n                  (ie, randomization).\n\n                  3. Male or non-pregnant and non-lactating female, and \u2265 18 years of age at the\n                  time of signing the informed consent document.\n\n               -  If heterosexually active, the subject must agree to use medical doctor-approved\n                  contraception throughout the study, and for 6 months after last dose of study\n                  drug.\n\n                  4. History of malignancy in the last 5 years; subjects with prior history of in\n                  situ cancer or basal or squamous cell skin cancer are eligible.\n\n               -  Subjects with other malignancies are eligible if they were cured by surgery\n                  (with or without radiotherapy) and have been continuously disease-free for at\n                  least 5 years.\n\n                  5. Radiographically-documented measurable disease (defined by the presence of at\n                  least one radiographically documented measurable lesion including measurable\n                  cutaneous metastasis).\n\n                  6. Adequate haemtological and biochemical parameters:\n\n               -  ANC \u2265 1.5 x 109 cells/L.\n\n               -  Platelets \u2265 100 x 109 cells/L.\n\n               -  Hgb \u2265 9 g/dL.\n\n               -  AST (SGOT) or ALT (SGPT) \u2265 2.5x upper limit of normal range (ULN);\n\n                  o \u2264 5.0 x ULN if hepatic metastases present.\n\n               -  Total bilirubin \u2264 ULN. Creatinine \u2264 1.5 mg/dL. 8. ECOG performance status 0 to\n                  1.\n\n        Exclusion Criteria:\n\n          -  1. History of or current evidence of symptomatic brain metastases (brain Computed\n             Tomography (CT)/Magnetic Resonance Imaging (MRI) is needed to exclude brain\n             metastasis), including leptomeningeal involvement.\n\n             2. Subject has pre-existing peripheral neuropathy of National Cancer Institute NCI\n             Common Terminology Criteria for Adverse Events (NCI CTCAE) Scale of Grade \u2265 2.\n\n             3. Prior radiation to a target lesion is permitted only if there has been clear\n             progression of the lesion since radiation was completed."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933061", 
            "org_study_id": "CC-486-MEL-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Abraxane 150 mg/m\u00b2 Intravenous (IV)", 
                "description": "Abraxane 150- mg/m\u00b2 IV on Days 1, 8, and 15 of a 28-day cycle", 
                "intervention_name": "Abraxane", 
                "intervention_type": "Drug", 
                "other_name": "nab-paclitaxel, ABI-007"
            }, 
            {
                "arm_group_label": "CC-486 orally plus Abraxane IV", 
                "description": "Abraxane 150 mg/m^2 intravenously on Days 1, 8, and 15 of a 28-day cycle", 
                "intervention_name": "Abraxane", 
                "intervention_type": "Drug", 
                "other_name": "nab-paclitaxel, ABI-007"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Skin cancer, Melanoma", 
        "lastchanged_date": "February 3, 2014", 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open Label, Multi-center Phase 2 Study of Nab-Paclitaxel Versus Epigenetic Modifying Therapy of CC-4386 With Nab-Paclitaxel in Subjects With Chemotherapy na\u00efve Metastatic Melanoma", 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Kirsten Hege, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "PFS is defined as the time from randomization date to disease progression according to RECIST response guideline", 
            "measure": "Progression-free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933061"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "OS is defined as the time from the date of randomization to the date of death.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "PFS based on investigator assessment; PFS is defined as the time from randomization date to disease progression according to RECIST response guideline", 
                "measure": "PFS", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "Number (%) of subject who achieve an objective complete or partial response.", 
                "measure": "Objective Response Rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "Number (%) of subject with Stable Disease (SD) \u2265 for  18 weeks or complete or partial response.", 
                "measure": "Disease Control Rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 months"
            }, 
            {
                "description": "Incidence and severity of Adverse events (AE) will be analyzed in terms of treatment-emergent AEs defined to be any AE that begin or worsen in severity after study drug initiation.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 months"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014", 
        "why_stopped": "Strategic decision not to proceed with the opening of this study. There are no concerns over\n    the safety or quality of the investigational products involved."
    }
}